Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
Status:
Completed
Trial end date:
2018-06-07
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and best dose of bortezomib when given with
chemotherapy and to see how well they work in treating participants with lymphoid
malignancies undergoing stem cell transplant. Giving chemotherapy before a stem cell
transplant helps stop the growth of cells in the bone marrow, including normal blood-forming
cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused
into the participant they may help the participant's bone marrow make stem cells, red blood
cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can
make an immune response against the body's normal cells called graft versus host disease.
Giving tacrolimus and methotrexate after the transplant may stop this from happening. Giving
bortezomib and chemotherapy may work better in treating participants with lymphoid
malignancies undergoing a stem cell transplant.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)